Pathophysiology and clinical management of cardiac sarcoidosis.
Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis.
Because GCM usually has diffuse or multifocal involvement of the endocardium, endomyocardial biopsy (EMB) tends to have a higher diagnostic sensitivity in GCM than in cardiac sarcoidosis (35%) or lymphocytic myocarditis (25%).
4) Foremost among these are cardiac sarcoidosis (CS) and fulminant lymphocytic myocarditis.
Table 1: Two Diagnostic Pathways for Establishing Cardiac Sarcoidosis
(CS) (8-9) 1.
Clinically significant cardiac sarcoidosis
is found in only 5 - 10% of subjects, and about 50% of these will have ECG abnormalities.
Arrhytmogenesis and diagnosis of cardiac sarcoidosis.
Sudden cardiac death from unrecognized cardiac sarcoidosis.
Detection of cardiac sarcoidosis
using cardiac markers and myocardial integrated backscatter.
is a poor prognostic indicator and is associated with ventricular tachyarrhythmias, conduction abnormalities, and LV dysfunction.
These findings were consistent with cardiac sarcoidosis
, and a transvenous pacemaker was placed.
CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis.
Cardiac sarcoidosis detected by late gadolinium enhancement and prevalence of atrial arrhythmias.
2) Cardiac sarcoidosis
is a subset of sarcoidosis that may precede, follow, or be concurrent with involvement of other organs.
Clinically relevant cardiac sarcoidosis
has a variable incidence depending on the population studied, (5) but among fatalities from sarcoidosis cardiac involvement is likely responsible for 50% of cases.